Anixa Biosciences wins Australian patent for breast cancer vaccine through 2040

Bitget2026/09/21 16:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Anixa Biosciences won its first Australian patent covering its breast cancer vaccine technology, extending exclusivity in Australia through 2040.
The issued composition-of-matter patent covers vaccine adjuvants and formulations licensed from Cleveland Clinic.
Anixa cited Phase 1 data showing the vaccine was safe, well tolerated, and triggered immune responses in more than 74% of participants.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609210845PR_NEWS_USPR_____LA51971) on September 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Anixa Biosciences wins Australian patent for breast cancer vaccine through 2040

You may also like

Crypto prices